PHILADELPHIA, Oct. 24, 2011 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex: HEB) (the "Company"), has scheduled a conference call and audio webcast on Thursday, October 27, 2011 at 2:00 p.m. (Eastern Time). In response to stockholder interest, the Company will host a call to provide a status report on Ampligen® as a treatment for Chronic Fatigue Syndrome (CFS). Management will provide a briefing and answer questions regarding the Company's pending New Drug Application (NDA) and the related Food and Drug Administration (FDA) Complete Response Letter. The Company will update scientific advances in Chronic Fatigue Syndrome and give an overview of new data of a potential diagnostic/prognostic blood test developed with Chronix Biomedical based on novel gene patterns identified in peripheral blood of CFS patients.
